[A25-83] Sarilumab (polymyalgia rheumatica) – Addendum to Project A25-18
Last updated 07.08.2025
Project no.:
A25-83
Commission:
Commission awarded on 24.06.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper
- Patients for whom corticosteroids are the appropriate treatment of physician’s choice: hint of a non-quantifiable added benefit
- Patients for whom the combination of corticosteroids with methotrexate is the appropriate treatment of physician’s choice: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-83
| Project no. | Title | Status |
|---|---|---|
| A25-18 | Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-08-2025 A G-BA decision was published.
G-BA documents on this decision